Name: MarketsandMarkets ImmunoBio Series 2024 - UK Edition
Start: 2024-03-07
End: 2024-03-08
Location: Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION
Keynote Presentation - ICT01, an anti-BTN3A mAb activating Vg9Vd2 cells Emmanuel Valentin, Vice President, Translational Medicine, Imcheck Therapeutics	09:00 - 09:30
Co -Presentations: 1.Biomarker assay development and validation for cancer treatment. 2. From Biomarker Discovery to Diagnostic: Navigating the Translational Journey Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG Valerie Balme, Associate Director, Business Development, Veracyte	09:30 - 10:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Transforming Oncology with Predicine’s Liquid Biopsy Solutions Shidong Jia, Founder, CEO, Predicine	11:15 - 11:45
Combination Strategies for Personalised Cancer Therapy Sreejith Raveendran, Assistant Professor, Teesside University	11:45 - 12:15
Sample quality strategies, operations and patient centricity for biomarker analysis Debora Souza Da Costa, Senior Biosample Project Leader., Roche	12:15 - 12:45
Comprehensive Biomarker Strategies To Decipher The Tumor Microenvironment: From Tissue To High-Quality Spatial Insights Angela Vasaturo , Director of Scientific Affairs, Ultivue	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE
AI-driven analysis of morphological biomarkers for trials in haemato-oncology Daniel Royston, Consultant Clinical Advisor, Ground Truth Labs	14:15 - 14:45
AI in medicine - A paradigm shift for the diagnostic industry Thomas Gohl, Market Development Manager, Roche Diagnostics	14:45 - 15:15
Development of a colorectal cancer methylation panel and an actionable cancer mutation panel using targeted bisulfite next-generation sequencing Collin Hudzik, Scientist in product and business development , EpigenDx	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Lifestyle and epigenetic changes Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby	16:30 - 17:00
Back translation of preclinical models to humans Maria Dermit, Computational Biologist, Novo Nordisk	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30
Drinks Reception & Networking	17:30 - 17:30
End of Day 1	17:30 - 17:35

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
NEW ANTIBODIES DEVELOPMENTS AND UPDATES
Keynote Presentation- HLA-agnostic T-cell recognition of cancer Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University	09:00 - 09:30
IgE Immunotherapy from Concept to Translation Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	09:30 - 10:00
Investigating PD-L1 expression in Circulating Tumor Cells of metastatic cancer patients, using Parsortix® system. Anne-Sophie Pailhes-Jimenez, Senior Director, Head of R&D, ANGLE Europe Limited	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Targeting myeloid cells to augment antibody immunotherapy Ali Roghanian, Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton	11:15 - 11:45
Co- Presentations: 1.From Biomarker Discovery to Diagnostic: Navigating the Translational Journey. 2. Biomarker assay development and validation for cancer treatment Valerie Balme, Associate Director, Business Development, Veracyte Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG	11:45 - 12:15
Fc Engineering to overcome suppressive tumour microenvironments Stephen Beers, Immunology and Immunotherapy, University of Southampton, Professor	12:15 - 12:45
Preclinical mouse models for I/O research Jianming Xu, Director, InVivo Pharmacology, GemPharmatech	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Boosting Cancer Therapy in immunotherapy with next microbiome generation co-cultured product Nathalie Corvaia, Chief Scientific Officer, MaaT Pharma	15:15 - 15:45
NEW ANTOBODY FORMATS AND TUMOR MICRO-ENVIROMENT
Gamma delta T cells as cancer immunotherapeutics Jonathan Fisher, T-Cell Immunotherapy, Group Leader, University College London	14:15 - 14:45
A novel redirecting antibody targeting SCLC Lindy Durrant, Professor of Cancer Immunotherapy, CEO, ScanCell Ltd	14:45 - 15:15
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Tumour micro environment and CAR-T Cell Therapy Etienne De Braekeleer, Senior Scientist - Cell Biology & Research Immunology, AstraZeneca	16:30 - 17:00
iPSC derived cell therapies for the treatment of cancer Michael Epstein, VP, Head of Translational Research, Evotec	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES
Keynote Presentation- CAR T-cell immunotherapy of solid tumours: moving through the generations John Maher, Chief Scientific Officer, Leucid Bio	09:00 - 09:30
A novel Neuropilin-1 (NRP1) antisense oligonucleotide (ASO) with strong in vivo antitumor activity as single agent and in combination with immune checkpoint inhibitors Konstantin Petropoulos, Chief Business Officer, Secarna Pharmaceuticals	09:30 - 10:00
Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment Mark Eccleston, Founder and Chief Technology Officer, Volition	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Precise spatial multiplexing with ChipCytometry: An open-source solution to high-throughput spatial biology Anders Eriksson, Lead Field Application Scientist , Canopy Biosciences	11:15 - 11:45
Programmable and autoregulated viral vectors for new applications of gene therapy Farzin Farzaneh, CSO, ViroCell Biologics Ltd Professor of Molecular Medicine, King’s College London	11:45 - 12:15
.... Joanna Brewer, Chief Scientific Officer, Adaptimmune	12:15 - 12:45
T cell mechanostimulation as a promising approach for enhancing immunotherapies Sebastian Lickert, Group Lead, ETH Zürich	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	14:15 - 14:45
Monocytes and Macrophages in Ovarian Cancer, Biomarker and therapeutic Opportunities in their Overlooked immune Checkpoints Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey	14:45 - 15:15
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDCline) Eric Halioua,* President & Chief Executive Officer, PDC*line pharma SA	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
... Phillip Brailey, Senior Scientist, Crescendo Biologics	16:30 - 17:00
Oncolytic viruses in the era of Checkpoint Blockade	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION
Keynote Presentation : Use of biomarkers in clinical development to guide dosing regimen recommendation with the use of modelling and simulations models. Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB	09:00 - 09:30
Tracking challenging pharmacodynamic biomarkers in normal tissue on Phase I clinical trials of new oncology agents Karen Swales, Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research	09:30 - 10:00
With only 1/500 Biomarkers reaching the patient what can we do better? Christopher Peters, Clinical Senior Lecturer, Imperial College London	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES
Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions. Louis Boon, CSO , JJP Biologics	11:15 - 11:45
The Lymphocyte Stability Index - a pan-cancer biomarker for response to immune checkpoint blockade Robert Watson, Clinical Lecturer, University of Oxford	11:45 - 12:15
Histone based liquid biopsies for the screening of cancer and cardiovascular diseases Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool	12:15 - 12:45
Generating pseudo-time progression of mucosal inflammation during Inflammatory Bowel Disease using spatially resolved multi-omics data Priyank Patel, Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Panel Discussion: Moderator : What are the biggest challenges faced in developing an assay: why and what have we learnt from it ? Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB Christopher Peters, Clinical Senior Lecturer, Imperial College London Maria Dermit, Computational Biologist, Novo Nordisk Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey	14:15 - 14:45
Closing Remarks from the Chairperson	14:45 - 14:50
END OF CONFERENCE	14:50 - 14:50

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY
Keynote Presentation: Cross Training technology: augmenting cross-presentation of neo-antigens Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics	09:00 - 09:30
Personalized Immunotherapies: Past, Present and Future Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca	09:30 - 10:00
Unlocking IL-2 therapeutic power using Attenukine™ platform Iris Hecht, Sr. Director, Project Leader, Specialty Projects, Teva Pharmaceuticals	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
LATEST DEVELOPMENTS & TRENDS IN IO RESEARCH
Generative AI designed Personalized Neoantigen Vaccines Daniela Kleine-Kohlbrecher, Senior Project Manager Immune Oncology, Evaxion Biotech	11:15 - 11:45
Exploring γδT Reprogramming as a Solution for Donor Material Access and Donor-to-Donor Variability Daria Paruzina, Senior Manager of Product Development and Platform Expansion, TC BioPharm	11:45 - 12:15
Cross Training technology: augmenting cross-presentation of neo-antigens Raj Mehta, Founder, Chief Executive Officer & Director, Adendra Therapeutics	12:15 - 12:45
Cancer Vaccines: bringing safety and specificity to immunotherapy John Maudsley, CEO, Cancer Vaccines Ltd	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care John Maher, Chief Scientific Officer, Leucid Bio John Maudsley, CEO, Cancer Vaccines Ltd Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca Louis Boon, CSO , JJP Biologics	14:15 - 14:45
Closing Remarks from the Chairperson	14:45 - 14:50

SPEAKERS

Anne-Sophie Pailhes-Jimenez

Senior Director, Head of R&D, ANGLE Europe Limited

Joanna Brewer

Chief Scientific Officer, Adaptimmune

Robert Watson

Clinical Lecturer, University of Oxford

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Nathalie Corvaia

Chief Scientific Officer, MaaT Pharma

John Maher

Chief Scientific Officer, Leucid Bio

Valerie Balme

Associate Director, Business Development, Veracyte

Debora Souza Da Costa

Senior Biosample Project Leader., Roche

Etienne De Braekeleer

Senior Scientist - Cell Biology & Research Immunology, AstraZeneca

Louis Boon

CSO , JJP Biologics

Nathalie Steinhoff

Scientist, Cancer Immunotherapy, Numab Therapeutics AG

Eike Staub

Head, Oncology Bioinformatics, Merck Healthcare, Germany

Ali Roghanian

Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton

Senior Representative, Ground Truth Labs

Senior Representative, Ground Truth Labs

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Michael Epstein

VP, Head of Translational Research, Evotec

Anil Thotakura

Head of Immuno-Oncology, Orion Pharmaceuticals

Christian Garde

Scientific Director, Bioinformatics, Evaxion Biotech A/S

John Maudsley

CEO, Cancer Vaccines Ltd

Iris Hecht

Sr. Director, Project Leader, Specialty Projects, Teva Pharmaceuticals

Anders Eriksson

Lead Field Application Scientist , Canopy Biosciences

Priyank Patel

Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc

Fernando Oneissi Martinez Estrada

Senior Lecturer in Innate Immunology, University of Surrey

Mark Eccleston

Founder and Chief Technology Officer, Volition

Thomas Gohl

Market Development Manager, Roche Diagnostics

Manlio Vinciguerra

European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool

Shidong Jia

Founder, CEO, Predicine

Patrick Brossard

Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

Jelmar Quist

Cancer Bioinformatician, King’s College London

Anne-Sophie Pailhes-Jimenez

Senior Director, Head of R&D, ANGLE Europe Limited

Daniela Kleine-Kohlbrecher

Senior Project Manager Immune Oncology, Evaxion Biotech

Georges Rawadi

CEO, Celyad Oncology

Christopher Peters

Clinical Senior Lecturer, Imperial College London

Sebastian Lickert

Group Lead, ETH Zürich

Senior Representative, Gempharmatech

Senior Representative,, Gempharmatech

Konstantin Petropoulos

Chief Business Officer, Secarna Pharmaceuticals

Senior Representative, Canopy Biosciences

Stephen Beers

Immunology and Immunotherapy, University of Southampton, Professor

Jonathan Fisher

T-Cell Immunotherapy, Group Leader, University College London

Daniel Royston

Consultant Clinical Advisor, Ground Truth Labs

Farzin Farzaneh

CSO, ViroCell Biologics Ltd Professor of Molecular Medicine, King’s College London

Emmanuel Valentin

Vice President, Translational Medicine, Imcheck Therapeutics

Aparna Duggirala

Lecturer, Clinical Genetics, University of Derby

Pedro Correa de Sampaio

Co-Founder, CEO,, Neobe Therapeutics

Lindy Durrant

Professor of Cancer Immunotherapy, CEO, ScanCell Ltd

Maria Dermit

Computational Biologist, Novo Nordisk

Sreejith Raveendran

Assistant Professor, Teesside University

Angela Vasaturo

Director of Scientific Affairs, Ultivue

Grab before it's gone. Avail 30% Instant Discount

ImmunoBio Series 2024 - UK Edition

Bridging Science, Innovation, and Health for a Better Tomorrow

CO-LOCATED CONFERENCES

WHAT TO EXPECT

CONFERENCE AGENDA

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE

NEW ANTIBODIES DEVELOPMENTS AND UPDATES

NEW ANTOBODY FORMATS AND TUMOR MICRO-ENVIROMENT

CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES

NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES

PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY

LATEST DEVELOPMENTS & TRENDS IN IO RESEARCH

SPEAKERS

Anne-Sophie Pailhes-Jimenez

Joanna Brewer

Robert Watson

Elizabeth Sheppard

Nathalie Corvaia

John Maher

Valerie Balme

Debora Souza Da Costa

Etienne De Braekeleer

Louis Boon

Nathalie Steinhoff

Eike Staub

Ali Roghanian

Senior Representative, Ground Truth Labs

Sophia Karagiannis

Michael Epstein

Anil Thotakura

Christian Garde

John Maudsley

Iris Hecht

Anders Eriksson

Priyank Patel

Fernando Oneissi Martinez Estrada

Mark Eccleston

Thomas Gohl

Manlio Vinciguerra

Shidong Jia

Patrick Brossard

Jelmar Quist

Anne-Sophie Pailhes-Jimenez

Daniela Kleine-Kohlbrecher

Georges Rawadi

Christopher Peters

Sebastian Lickert

Senior Representative, Gempharmatech

Konstantin Petropoulos

Senior Representative, Canopy Biosciences

Stephen Beers

Jonathan Fisher

Daniel Royston

Farzin Farzaneh

Emmanuel Valentin

Aparna Duggirala

Pedro Correa de Sampaio

Lindy Durrant

Maria Dermit

Sreejith Raveendran

Angela Vasaturo

ENQUIRE NOW

SPONSORS

LOCATION

Venue

PAST EVENT GALLERY

24/7 Customer Support